Abstract:Anxiety disorders are prevalent and disabling yet understudied from a genetic standpoint, compared with other major psychiatric disorders such as bipolar disorder and schizophrenia. The fact that they are more common, diverse and perceived as embedded in normal life may explain this relative oversight. In addition, as for other psychiatric disorders, there are technical challenges related to the identification and validation of candidate genes and peripheral biomarkers. Human studies, particularly genetic ones, are susceptible to the issue of being underpowered, because of genetic heterogeneity, the effect of variable environmental exposure on gene expression, and difficulty of accrual of large, well phenotyped cohorts. Animal model gene expression studies, in a genetically homogeneous and experimentally tractable setting, can avoid artifacts and provide sensitivity of detection. Subsequent translational integration of the animal model datasets with human genetic and gene expression datasets can ensure cross-validatory power and specificity for illness. We have used a pharmacogenomic mouse model (involving treatments with an anxiogenic drug—yohimbine, and an anti-anxiety drug—diazepam) as a discovery engine for identification of anxiety candidate genes as well as potential blood biomarkers. Gene expression changes in key brain regions for anxiety (prefrontal cortex, amygdala and hippocampus) and blood were analyzed using a convergent functional genomics (CFG) approach, which integrates our new data with published human and animal model data, as a translational strategy of cross-matching and prioritizing findings. Our work identifies top candidate genes (such as FOS, GABBR1, NR4A2, DRD1, ADORA2A, QKI, RGS2, PTGDS, HSPA1B, DYNLL2, CCKBR and DBP), brain–blood biomarkers (such as FOS, QKI and HSPA1B), pathways (such as cAMP signaling) and mechanisms for anxiety disorders—notably signal transduction and reactivity to environment, with a prominent role for the hippocampus. Overall, this work complements our previous similar work (on bipolar mood disorders and schizophrenia) conducted over the last decade. It concludes our programmatic first pass mapping of the genomic landscape of the triad of major psychiatric disorder domains using CFG, and permitted us to uncover the significant genetic overlap between anxiety and these other major psychiatric disorders, notably the under-appreciated overlap with schizophrenia. PDE10A, TAC1 and other genes uncovered by our work provide a molecular basis for the frequently observed clinical co-morbidity and interdependence between anxiety and other major psychiatric disorders, and suggest schizo-anxiety as a possible new nosological domain.

Transcriptome-Wide Association Study Provides Insights Into the Genetic Component of Gene Expression in Anxiety

Genome-wide meta-analysis, functional genomics and integrative analyses implicate new risk genes and therapeutic targets for anxiety disorders

Transcriptome-wide Association Study Identifies New Susceptibility Genes and Pathways for Depression

Nominating novel proteins for anxiety via integrating human brain proteomes and genome-wide association study

Identification of Novel Rare Variants for Anxiety: an Exome-Wide Association Study in the UK Biobank

Proteome-wide Association Study Provides Insights Into the Genetic Component of Protein Abundance in Psychiatric Disorders

Brain transcriptome-wide association study implicates novel risk genes underlying schizophrenia risk

Genome-wide association studies in non-anxiety individuals identified novel risk loci for depression

Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling

Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms

Integrating Genome-Wide Association Study and Expression Quantitative Trait Loci Data Identifies Multiple Genes and Gene Set Associated with Neuroticism.

Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study

Identification of novel genomic loci for anxiety symptoms and extensive genetic overlap with psychiatric disorders

A single-nucleus transcriptome-wide association study implicates novel genes in depression pathogenesis

Gene Discovery and Biological Insights into Anxiety Disorders from a Multi-Ancestry Genome-wide Association Study of >1.2 Million Participants

Meta-analyses of genome-wide linkage scans of anxiety-related phenotypes

An Integrative Analysis of Transcriptome-Wide Association Study and Mrna Expression Profile Identified Candidate Genes for Attention-Deficit/hyperactivity Disorder.

Analysis of common genetic variation of anxiety disorders in essential tremor

Epigenetic Element-Based Transcriptome-Wide Association Study Identifies Novel Genes for Bipolar Disorder

A Genome-Wide Multiphenotypic Association Analysis Identified Common Candidate Genes for Subjective Well-Being, Depressive Symptoms and Neuroticism

Integrating Genome-Wide Association Study and Expression Quantitative Trait Locus Study Identifies Multiple Genes and Gene Sets Associated with Schizophrenia